Cynata Therapeutics (ASX:CYP) Presentation, FNN Investor Event, October 2017, Sydney

Company Presentations

Cynata Therapeutics Limited (ASX:CYP) Managing Director and CEO Dr Ross Macdonald provides an overview of the company's stem cell manufacturing platform, commercialisation pathway and strategy.

Key points:

 - Developing a novel therapeutic stem cell (MSC) technology: CymerusTM
 - World-first Phase I clinical trial commenced in Graft vs Host disease (GvHD); sites in UK and Australia
 - Strategic partnership with Japanese regenerative medicine company, Fujifilm Corporation
 - License option agreement with apceth GmbH & Co. KG for several disease target areas - Strong balance sheet: cash runway into 2019 based on current projections
 - Compelling preclinical data from a range of animal proof-of-concept studies in asthma, heart attack and critical limb ischemia.
 - Broad commercial potential in a range of diseases including stroke, heart disease and osteoarthritis
 - Regenerative medicine industry expected to grow to over $53.7 billion by 2021. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.